280 related articles for article (PubMed ID: 20300113)
21. The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro.
Blake S; Hughes TP; Mayrhofer G; Lyons AB
Clin Immunol; 2008 Jun; 127(3):330-9. PubMed ID: 18395492
[TBL] [Abstract][Full Text] [Related]
22. Type 4 cAMP phosphodiesterase (PDE4) inhibitors augment glucocorticoid-mediated apoptosis in B cell chronic lymphocytic leukemia (B-CLL) in the absence of exogenous adenylyl cyclase stimulation.
Tiwari S; Dong H; Kim EJ; Weintraub L; Epstein PM; Lerner A
Biochem Pharmacol; 2005 Feb; 69(3):473-83. PubMed ID: 15652238
[TBL] [Abstract][Full Text] [Related]
23. Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells.
Nam S; Williams A; Vultur A; List A; Bhalla K; Smith D; Lee FY; Jove R
Mol Cancer Ther; 2007 Apr; 6(4):1400-5. PubMed ID: 17431118
[TBL] [Abstract][Full Text] [Related]
24. Superantigen stimulation reveals the contribution of Lck to negative regulation of T cell activation.
Criado G; Madrenas J
J Immunol; 2004 Jan; 172(1):222-30. PubMed ID: 14688329
[TBL] [Abstract][Full Text] [Related]
25. The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes.
Veldurthy A; Patz M; Hagist S; Pallasch CP; Wendtner CM; Hallek M; Krause G
Blood; 2008 Aug; 112(4):1443-52. PubMed ID: 18550857
[TBL] [Abstract][Full Text] [Related]
26. Akt inhibitors induce apoptosis in chronic lymphocytic leukemia cells.
de Frias M; Iglesias-Serret D; Cosialls AM; Coll-Mulet L; Santidrián AF; González-Gironès DM; de la Banda E; Pons G; Gil J
Haematologica; 2009 Dec; 94(12):1698-707. PubMed ID: 19815839
[TBL] [Abstract][Full Text] [Related]
27. SAP facilitates recruitment and activation of LCK at NTB-A receptors during restimulation-induced cell death.
Katz G; Krummey SM; Larsen SE; Stinson JR; Snow AL
J Immunol; 2014 May; 192(9):4202-9. PubMed ID: 24688028
[TBL] [Abstract][Full Text] [Related]
28. Profound inhibition of antigen-specific T-cell effector functions by dasatinib.
Weichsel R; Dix C; Wooldridge L; Clement M; Fenton-May A; Sewell AK; Zezula J; Greiner E; Gostick E; Price DA; Einsele H; Seggewiss R
Clin Cancer Res; 2008 Apr; 14(8):2484-91. PubMed ID: 18413841
[TBL] [Abstract][Full Text] [Related]
29. Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway.
Zauli G; Voltan R; Bosco R; Melloni E; Marmiroli S; Rigolin GM; Cuneo A; Secchiero P
Clin Cancer Res; 2011 Feb; 17(4):762-70. PubMed ID: 21106726
[TBL] [Abstract][Full Text] [Related]
30. Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis.
Contri A; Brunati AM; Trentin L; Cabrelle A; Miorin M; Cesaro L; Pinna LA; Zambello R; Semenzato G; Donella-Deana A
J Clin Invest; 2005 Feb; 115(2):369-78. PubMed ID: 15650771
[TBL] [Abstract][Full Text] [Related]
31. GM1 controlled lateral segregation of tyrosine kinase Lck predispose T-cells to cell-derived galectin-1-induced apoptosis.
Novák J; Kriston-Pál É; Czibula Á; Deák M; Kovács L; Monostori É; Fajka-Boja R
Mol Immunol; 2014 Feb; 57(2):302-9. PubMed ID: 24231767
[TBL] [Abstract][Full Text] [Related]
32. Glucocorticoids downregulate Fyn and inhibit IP(3)-mediated calcium signaling to promote autophagy in T lymphocytes.
Harr MW; McColl KS; Zhong F; Molitoris JK; Distelhorst CW
Autophagy; 2010 Oct; 6(7):912-21. PubMed ID: 20814235
[TBL] [Abstract][Full Text] [Related]
33. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
[TBL] [Abstract][Full Text] [Related]
34. Update on lymphocyte specific kinase inhibitors: a patent survey.
Martin MW; Machacek MR
Expert Opin Ther Pat; 2010 Nov; 20(11):1573-93. PubMed ID: 20831362
[TBL] [Abstract][Full Text] [Related]
35. TCR-induced T cell activation leads to simultaneous phosphorylation at Y505 and Y394 of p56(lck) residues.
Nyakeriga AM; Garg H; Joshi A
Cytometry A; 2012 Sep; 81(9):797-805. PubMed ID: 22674786
[TBL] [Abstract][Full Text] [Related]
36. Expression of the T-cell-specific tyrosine kinase Lck in normal B-1 cells and in chronic lymphocytic leukemia B cells.
Majolini MB; D'Elios MM; Galieni P; Boncristiano M; Lauria F; Del Prete G; Telford JL; Baldari CT
Blood; 1998 May; 91(9):3390-6. PubMed ID: 9558397
[TBL] [Abstract][Full Text] [Related]
37. Src-kinase inhibitors sensitize human cells of myeloid origin to Toll-like-receptor-induced interleukin 12 synthesis.
Wölfl M; Schwinn S; Yoo YE; Reß ML; Braun M; Chopra M; Schreiber SC; Ayala VI; Ohlen C; Eyrich M; Beilhack A; Schlegel PG
Blood; 2013 Aug; 122(7):1203-13. PubMed ID: 23836556
[TBL] [Abstract][Full Text] [Related]
38. The ibrutinib B-cell proliferation inhibition is potentiated in vitro by dexamethasone: Application to chronic lymphocytic leukemia.
Manzoni D; Catallo R; Chebel A; Baseggio L; Michallet AS; Roualdes O; Magaud JP; Salles G; Ffrench M
Leuk Res; 2016 Aug; 47():1-7. PubMed ID: 27235717
[TBL] [Abstract][Full Text] [Related]
39. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia.
Buchner M; Baer C; Prinz G; Dierks C; Burger M; Zenz T; Stilgenbauer S; Jumaa H; Veelken H; Zirlik K
Blood; 2010 Jun; 115(22):4497-506. PubMed ID: 20335218
[TBL] [Abstract][Full Text] [Related]
40. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner.
Seggewiss R; Loré K; Greiner E; Magnusson MK; Price DA; Douek DC; Dunbar CE; Wiestner A
Blood; 2005 Mar; 105(6):2473-9. PubMed ID: 15572591
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
